Sign up to save your podcasts
Or
Share FDA Grants Priority Review to Esbriet for Unclassifiable Interstitial Lung Disease
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Grants Priority Review to Esbriet for Unclassifiable Interstitial Lung Disease
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article announcing a priority review by the FDA on using Esbriet as a treatment for Unclassifiable Interstitial Lung Diseases (UILDs). Currently, there are no treatment options to slow the fibrotic progression for patients living with a UILD so the priority review, pending it’s results, could bring hope for people who otherwise have no option to treat their UILD.
Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
View all episodes
By Pulmonary Fibrosis NewsPulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article announcing a priority review by the FDA on using Esbriet as a treatment for Unclassifiable Interstitial Lung Diseases (UILDs). Currently, there are no treatment options to slow the fibrotic progression for patients living with a UILD so the priority review, pending it’s results, could bring hope for people who otherwise have no option to treat their UILD.
Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com